2018-05-31T11:19:35-05:00 2017-09-30 910189318 Moss Adams LLP 101 Second Street Suite 900 San Francisco CA 94105 990 2016-10-01 770207331 Palo Alto Veterans Institute for Research PALO 6508583970 3801 Miranda Avenue Palo Alto CA 94304 Michael A Hindery CEO 6508583970 2018-05-29 1 Richard Croghan P00089862 4159561500 2018-05-29 2016 2022-09-23 18:48:47Z Michael A Hindery 3801 Miranda Avenue Palo Alto CA 94304 28245650 0 X www.pavir.org X 1988 CA Advance veteran and public health through innovative research. 11 2 313 12 0 0 23247661 22428354 4963804 5764860 2208 36210 6300 10961 28219973 28240385 0 0 0 0 15765025 16118014 0 0 0 11121114 11567864 26886139 27685878 1333834 554507 10945542 13757503 3175921 5466398 7769621 8291105 X See Schedule O 0 0 1455623 PREDICTING RESILIENCE IN THE HUMAN MICROBIOME - DAVID RELMAN, MDDR. DAVID RELMAN IS THE PROJECT DIRECTOR OF ONE OF PAVIR'S LARGEST, MULTI-YEAR RESEARCH PROJECTS. IT IS ON THE CUTTING EDGE OF EXAMINING THE HUMAN MICROBIOME, THE COLLECTIVE GENOMES OF THE MICRO-ORGANISMS THAT RESIDE IN HUMANS. SPECIFICALLY, THE PROJECT AIMS TO ANSWER QUESTIONS RELATING TO RESILIENCE IN THE HUMAN MICROBIOME. HUMANS HAVE CO-EVOLVED WITH COMPLEX, DYNAMIC MICROBIAL COMMUNITIES THAT PLAY ESSENTIAL ROLES IN NUTRITION, METABOLISM, IMMUNITY, AND NUMEROUS OTHER ASPECTS OF HUMAN PHYSIOLOGY. HENCE, MAINTENANCE AND RECOVERY OF KEY BENEFICIAL SERVICES BY THE MICROBIOTA IN THE FACE OF DISTURBANCE IS FUNDAMENTAL TO HEALTH. THE GOAL IS TO IDENTIFY FEATURES OF THE HUMAN MICROBIOME THAT PREDICT MICROBIAL COMMUNITY STABILITY AND RESILIENCE FOLLOWING DISTURBANCE. THE BREADTH AND MAGNITUDE OF THIS PROJECT'S IMPACT ARE SIGNIFICANT: THE STUDY TEAM TESTS TO PREDICT MICROBIAL COMMUNITY RESPONSES TO DISTURBANCE, AND WORKS ON PROCEDURES TO STABILIZE OR RESTORE BENEFICIAL MICROBIAL INTERACTIONS AS NEEDED. A PREDICTIVE UNDERSTANDING OF THE STABILITY AND RESILIENCE OF THE GUT MICROBIOTA WILL ADVANCE THE RATIONAL PRACTICE OF MEDICINE. THIS PROJECT'S PARTICIPANT RECRUITMENT IS NEARLY COMPLETE, AND DATA COLLECTION HAS BEEN OPTIMIZED RESULTING IN A REDUCTION OF TECHNICAL VARIANCE AND REDUCED COMPLEXITY OF THE OVERALL PROTOCOL. AN ADDITIONAL AREA OF RECENT PROGRESS HAS BEEN IN DEVELOPING STANDARDS TO USE A LIQUID HANDLING ROBOT TO FACILITATE SEVERAL STEPS OF THE OVERALL WORK FLOW. 959086 1924465 A PROSPECTIVE INVESTIGATION OF THE RISKS OF OPIOID MISUSE, ABUSE, AND ADDICTION AMONG PATIENTS TREATED WITH EXTENDED-RELEASE/LONG ACTING (ER/LA) OPIOIDS FOR TREATMENT OF CHRONIC PAIN - SESHADRI MUDUMBAI, MD, MS. THIS STUDY EXAMINES THE MAGNITUDE OF MISUSE, ABUSE, AND ADDICTION AMONG PATIENTS WHO ARE TREATED WITH OPIOIDS FOR CHRONIC PAIN WHILE HAVING COMORBIDITY OF OPIOID USE DISORDER WITH OTHER SUBSTANCE USE AND PSYCHIATRIC DISORDERS AND ESTIMATES HOW THE RISK OF THESE OUTCOMES VARIES BY THE PRESENCE OF RISK FACTORS AMONG PATIENTS TREATED WITH OPIOIDS LONG-TERM. THE PUBLIC HEALTH CRISIS OF OPIOID MISUSE, ADDICTION AND OVERDOSE IS ONE OF THE MOST CHALLENGING ISSUES FACED BY AMERICAN SOCIETY. THE ISSUE CUTS ACROSS EVERY SOCIOECONOMIC LEVEL AND GEOGRAPHIC BOUNDARY. EVERY COMMUNITY IN AMERICA HAS BEEN TOUCHED BY FRIENDS, FAMILY MEMBERS OR COLLEAGUES SUFFERING FROM OPIOID ADDICTION, AND FAR TOO OFTEN, LOSING THEIR LIVES TO IT. OVER THE PAST FEW YEARS, THE FDA HAS TAKEN MANY ACTIONS TO HELP REDUCE THE NUMBER OF PEOPLE WHO BECOME ADDICTED, OR ULTIMATELY OVERDOSE FROM PRESCRIPTION OPIOIDS. TO COMBAT THIS EPIDEMIC, THE FDA MANDATED THAT PHARMACEUTICAL COMPANIES HOLDING NEW DRUG APPLICATIONS (NDA) OF EXTENDED-RELEASE/LONG LASTING (ER/LA) OPIOIDS CONDUCT ONE OR MORE STUDIES TO PROVIDE QUANTITATIVE ESTIMATES OF SERIOUS RISKS OF MISUSE, ABUSE, ADDICTION, OVERDOSE, AND DEATH ASSOCIATED WITH LONG-TERM USE OF OPIOIDS FOR MANAGEMENT OF CHRONIC PAIN, AMONG PATIENTS PRESCRIBED ER/LA OPIOID PRODUCTS. ALTHOUGH ABUSE AND MISUSE OF PRESCRIPTION OPIOIDS HAVE INCREASED OVER THE PAST DECADE, THERE IS DEBATE ABOUT THE MAGNITUDE OF MISUSE, ABUSE, AND ADDICTION AMONG PATIENTS WHO ARE TREATED WITH OPIOIDS FOR CHRONIC PAIN. FURTHER, ALTHOUGH THERE APPEARS TO BE COMORBIDITY OF OPIOID USE DISORDER WITH OTHER SUBSTANCE USE AND PSYCHIATRIC DISORDER, THERE IS INSUFFICIENT DATA TO ESTIMATE HOW THE RISK OF THESE OUTCOMES VARIES BY THE PRESENCE OF RISK FACTORS AMONG PATIENTS TREATED WITH OPIOIDS LONG-TERM. 713227 A BIOORTHOGONAL APPROACH TO STUDY MAMMALIAN AGING - TONY WYSS-CORAY, PH.D. AGING IS THE MAJOR RISK FACTOR FOR MOST OF THE LEADING CAUSES OF DEATH IN THE U.S., INCLUDING HEART DISEASE, CANCER, STROKE AND DEMENTIA. DR. WYSS-CORAY'S LABORATORY IS WORKING ON A NEW TECHNOLOGY WHICH WILL IDENTIFY FACTORS THAT CAN REJUVENATE THE BRAIN AND OTHER ORGANS AND ACCELERATE OUR UNDERSTANDING OF THE BASIC BIOLOGY OF AGING. THE WYSS-CORAY LABORATORY IS POISED TO FACILITATE THE IDENTIFICATON, LOCALIZATION, AND TRACKING OF FACTORS SECREATED FROM SPECIFIC ORGANELLES, CELL TYPES, OR ORGANS IN VIVO. THIS IS TRULY INNOVATIVE AND HAS NOT BEEN DONE BEFORE. THE POTENTIAL APPLICATIONS OF THIS TECHNOLOGY FOR DISEASE AND BIOLOGICAL RESEARCH IN GENERAL COULD BE ENORMOUS, AND WILL GET US CLOSER TO ANSWERING FUNDAMENTAL QUESTIONS ON WHAT CONTROLS ORGANISMAL AGING. THESE QUESTIONS INCLUDE WHETHER AGING STARTS IN ONE TISSUE AND SPREADS TO ANOTHER, OR STARTS IN ONE CELL TYPE AND SPREADS TO OTHER CELLS AND TISSUES, OR STARTS SIMULTANEOUSLY IN ALL CELLS, OR DRIVEN BY OTHER FACTORS. THIS PROJECT FOLLOWS A PREVIOUS GROUNDBREAKING DISCOVERY IN DR. WYSS-CORAY'S LABORATORY THAT SOLUBLE, HEAT LABILE FACTORS IN BLOOD PLASMA ARE SUFFICIENT TO ACCELERATE BRAIN AGING OR REGENERATE AND REJUVINATE OLD BRAINS. 20440906 3840395 PAVIR IS PRIVILEGED TO WORK WITH A LARGE COMMUNITY OF UNIQUELY TALENTED MEDICAL RESEARCHERS ACROSS A BROAD SPECTRUM OF RESEARCH AREAS AS WE FULFILL OUR MISSION OF ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. THE RANGE OF RESEARCH ACTIVITIES IS BROAD AND INCLUDES SPECIAL EMPHASIS ON MAJOR DISEASE CATEGORIES, ALL OF WHICH ARE PREVALENT IN THE VA'S PATIENT POPULATION. THESE INCLUDE CARDIOVASCULAR MEDICINE, MENTAL HEALTH, CHRONIC INFLAMMATORY DISEASE, STEM CELL/REGENERATIVE MEDICINE, PAIN, SLEEP DISORDERS, AND MANY OTHERS. IN ADDITION TO DISEASE SPECIFIC RESEARCH, PAVIR IS ENGAGED IN SUPPORTING RESEARCH AIMED AT ENHANCING HEALTH CARE. PAVIR'S RESEARCH PORTFOLIO INCLUDES COMPARATIVE STUDIES IN WHICH RESEARCH TEAMS ARE LEARNING WHICH TREATMENTS ARE SUPERIOR TO OTHERS, HOW TO AUGMENT OR IMPROVE STANDARD OF CARE, AS WELL AS HOW TO ENHANCE THE OPERATION OF HEALTH CARE. FURTHERMORE, PAVIR IS SUPPORTING EDUCATIONAL ACTIVITIES, ESPECIALLY IN AREAS OF ADVANCING CLINICAL CARE FOR VETERANS AND FOSTERING THE PROFESSIONAL DEVELOPMENT OF OUR EXPERT STAFF. 20440906 3840395 23568842 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 53 0 1 313 1 0 0 0 0 0 0 0 0 0 0 X 11 2 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X Lily Ibragimov 6508583970 3801 Miranda Avenue Palo Alto CA 94304 Thomas J Fitzgerald III Statutory VA Director 0.50 40.00 X 0 0 0 Charlie Conz Director 0.50 0.00 X 0 0 0 Mary K Goldstein Director 0.50 40.00 X 0 0 0 Lawrence Leung Statutory VA Director, Secr./Treas. 1.00 40.00 X X 0 0 0 David J Clark Director 0.50 40.00 X 0 0 0 Odette Harris Director 0.50 40.00 X 0 0 0 Philip Tsao Statutory VA Dir/Aud Committee Chair 1.00 40.00 X 0 0 0 Mark Nicolls Director, Board Chair 1.00 40.00 X X 0 0 0 Ferid Murad Director 10.00 0.00 X 0 0 0 John Pollard Statutory VA Dir/Aud Committee Memb 0.50 40.00 X 0 0 0 Robert Sloss Director 0.50 0.00 X 0 0 0 Phillip L Jelsma Director through 7/26/2017 0.50 0.00 X 0 0 0 Kerstin Lynam CEO 40.00 0.00 X 275453 0 35991 Bonnie Oiking Liang CFO/COO 40.00 0.00 X 207956 0 15578 Mary L Thornton Director of Data Integrity 40.00 0.00 X 131963 0 20218 Wen Amy Tian Research Scientist II 40.00 0.00 X 123860 0 18723 Lily Ibragimov Controller 40.00 0.00 X 123522 0 19279 Stephanie L Hensey Database Analyst II 40.00 0.00 X 119657 0 22311 Xinguo Jiang Research Scientist II 40.00 0.00 X 117400 0 23707 1099811 0 155807 17 0 1 0 Toussaint Bradford P 104 Loma Road San Carlos CA 94070 Lean Consulting Services 141525 Moss Adams LLP PO Box 101822 Pasadena CA 911891822 Auditing and Tax Services 105925 2 21576795 851559 22428354 Medical Research 541700 4704208 4704208 GOVT FEES & CONTRACTS 541700 1060652 1060652 5764860 41475 41475 5265 -5265 -5265 -5265 Miscellaneous Revenue 541700 10961 10961 10961 28240385 5764860 0 47171 618300 29948 588352 12610874 10607749 2003125 644475 500572 143903 1207453 1092600 114853 1036912 832448 204464 31640 6841 24799 93515 93515 2068077 1580252 487825 35724 25774 9950 348757 225906 122851 192332 176995 15337 185752 185752 215686 183509 32177 403272 396978 6294 42557 42557 Research Material Costs 3536371 3536315 56 Subrecipients 1901938 1901938 Personnel Cost 1764967 1639256 125711 Equipment Maintenance 339168 338337 831 408108 307672 100436 27685878 23568842 4117036 0 1506687 2928738 4088935 5657522 3902244 3682969 315443 312777 3389727 2219230 1132233 1170497 0 5000 10945542 13757503 2417447 3556650 758474 1909748 3175921 5466398 X 6811348 7800555 958273 490550 7769621 8291105 10945542 13757503 X 554507 -1586 -31437 X 0 1 X 1 1 1 X va palo alto health care system palo alto CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 1 348 0 0 0 348 0 Part II-B, Line 1: Our organization paid membership dues to the National Association of Veterans Research and Education Foundations (NAVREF). The reported figure is the portion of those dues which NAVREF estimates contributed to its lobbying activities. 3389727 2219230 1170497 1170497 X 28207362 -1586 -31437 -33023 28240385 0 28240385 27685878 0 27685878 0 27685878 Part X, Line 2: Palo Alto Veterans Institute for Research is a nonprofit corporation exempt from federal income tax under Internal Revenue Code section 501(c)(3) and state income tax under California Revenue and Taxation Code section 23701d. However, income from certain activities not directly related to the Organization's tax-exempt purpose may be subject to taxation as unrelated business income. The Organization qualifies for the charitable contribution deduction under IRC section 170(b)(1)(A)(iii) and has been classified as an Organization that is not a private foundation under section 509(a)(1). As of September 30, 2017, the Organization had no unrecognized tax benefits or uncertain tax positions requiring accrual. Therefore, no provision for income taxes has been provided in the financial statements. Part XI, Line 2d - Other Adjustments: Reversal of Prior Year Contributions -31,437. X X 0 0 0 0 0 0 0 0 0 Kerstin Lynam CEO 275453 0 0 0 0 0 23410 0 12581 0 311444 0 0 0 Bonnie Oiking Liang CFO/COO 207956 0 0 0 0 0 7763 0 7815 0 223534 0 0 0 Mary L Thornton Director of Data Integrity 131963 0 0 0 0 0 12150 0 8068 0 152181 0 0 0 Form 990, Part III, Line 1 Advancing Veteran and public health through innovative research. The Palo Alto Veterans Institute for Research (PAVIR) facilitates research and education activities conducted at the VA Palo Alto Health Care System (VAPAHCS). The range of research activities is broad and includes special emphasis on: cardiovascular medicine; cancer; mental health--including Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder (PTSD); chronic inflammatory disease; and stem cell/regenerative medicine. Genomic medicine is a major overarching interest in our pursuit of health improvements for Veterans. We believe that advances in genomics will make personalized medicine a reality. Form 990, Part VI, Section A, line 7a Four Directors of the organization shall be those persons holding the Veterans Affairs Palo Alto Health Care System (VAPAHCS) positions of Director, Chief of Staff, Associate Chief of Staff for Research and Development, and Associate Chief of Staff for Education. The remaining non-VA statutory and non-statutory positions are nominated by the Chair of the Board of Directors, Secretary/Treasurer, and CEO, and ultimately appointed by the VAPAHCS Director. Form 990, Part VI, Section A, line 7b The Secretary of Veterans Affairs has authorized the VAPAHCS Director to order the dissolution of the organization in the event of a determination that the organization is no longer serving the interest of the Veterans Health Administration. Form 990, Part VI, Section B, line 11b THE FORM 990 HAS BEEN PROVIDED TO ALL BOARD MEMBERS FOR THEIR REVIEW AND APPROVAL PRIOR TO THE FILING OF ALL RELATED TAX FORMS. Form 990, Part VI, Section B, line 12c Each year, PAVIR's directors, officers, and key employees must review PAVIR's Conflict of Interest Policy and complete and sign a Conflict of Interest Disclosure Questionnaire, disclosing any potential areas of conflict of interest occurring during the preceding 12 months. In addition, directors and officers are required to complete an annual conflict of interest policy training. If a potential conflict of interest arises subsequent to submitting a Disclosure Questionnaire or between submissions, a director, officer, or employee shall promptly bring the situation to the attention of the Chair of the Board (applicable for members of the Board, officers, and the CEO) or the CEO (for PAVIR administrative employees and employees directly or indirectly engaged in VA research or education). Whenever there is reason to believe that a potential conflict of interest exists between PAVIR and any board member, officer, or employee, the Board will promptly convene a meeting to determine whether a conflict exists and the appropriate response. A director, officer, or employee who has a potential conflict of interest with respect to a proposed PAVIR decision, policy, transaction, or arrangement will not participate in any way in, or be present during, the deliberations and decision-making vote of PAVIR with respect to such matter. The process and result of the deliberation is recorded in the minutes of the Board meeting. Form 990, Part VI, Section B, line 15 PAVIR conducted a compensation study for executive positions, utilizing data from comparable organizations based on geography, industry and revenue. The study was presented to the Board of Directors for review and approval. The Board convened an executive session, during which the compensation data was used to make executive compensation decisions. The Board decisions regarding executive compensation was documented in file. Form 990, Part VI, Section C, line 19 The audited financial statements, organizing/governing documents, and conflict of interest policy are available upon written request. Form 990, Part XI, line 9: Reversal of Prior Year Contributions -31,437. Form 990, PART VII AND SCHEDULE J, PART II: COMPENSATION FROM RELATED ORGANIZATION: ON 4/23/2018, THE CEO WROTE TO EACH OF THE 8 BOARD MEMBERS WHO ARE COMPENSATED BY THE VA PALO ALTO HEALTH CARE SYSTEM REQUESTING PERMISSION TO OBTAIN HIS/HER COMPENSATION INFORMATION FOR THE TAX YEAR ENDING 12/31/16. IN RESPONSE, ALL BOARD MEMBERS DECLINED IN WRITING TO PROVIDE THEIR COMPENSATION INFORMATION. NONE OF THE BOARD MEMBERS RECEIVE COMPENSATION IN RELATION TO THEIR DUTIES AS BOARD MEMBERS OF PAVIR. VA PALO ALTO HEALTH CARE SYSTEM 3801 MIRANDA AVENUE PALO ALTO CA 94304 941179505 tEACHING HOSPITAL, PROVIDING A FULL RANGE OF PATIENT CARE SERVICES CA 501(c)(1) N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0